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Optogenetic strategies for perturbation of neural circuit function have begun to revolutionize
systems neuroscience. Whereas optogenetics has proven to be a powerful approach for
studying neural systems, the tools to conduct these experiments are still continuously evolv-
ing. Here we briefly summarize available hardware and reagents that can be used for studying
behaviors related to reward and addiction. In addition, we discuss recent studies in which
these strategies have been applied to study neural circuit function in brain slices as well as
awake and behaving animals. Collectively, this work serves as a brief introduction to opto-
genetic techniques and highlights how these tools can be applied to elucidate the neural
circuits that underlie reward processing and addiction.
Determining causal relationships betweenneural function and behavior is crucial to
understanding the neuropathology underlying
addiction. Relationships between function and
behavior have traditionally been accomplished
by tissue lesioning techniques, electrical stimu-
lation, or pharmacological activation or inacti-
vation. Whereas these methods have uncovered
the basic neuroanatomical pathways that medi-
ate reward-related behavior, they often fail to
determine how a specific neural pathway or
which neuronal cell types mediate a given be-
havioral response. Site-directed pharmacologi-
cal manipulations can sometimes be used to
address genetically defined pathways (only if a
given population of neurons locally express a
specific receptor), but these manipulations are
often over longer timescales, which do not allow
for determining how neural activity is required
for discrete behavioral events, which can often-
times last for less than 1 sec. To investigate causal
relationships between genetically defined pop-
ulations of neurons and reward-seeking be-
havior, techniques allowing for precise control
of neural circuitry with millisecond precision
are required. Optogenetics allows for pathway-
specific manipulation of brain circuitry over a
range of timescales, which circumvents many
of the technical limitations associated with elec-
trical, lesioning, and pharmacological manipu-
lations. Finally, combining optogenetics with
slice electrophysiology and in vivo behavioral
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paradigms can yield an unprecedented insight
into how the neural circuitry mediates addic-
tion-related behaviors.
OPSINS AND HARDWARE TO CONTROL
SPECIFIC NEURONAL PATHWAYS WITH
LIGHT
For a full description of the specific opsin pro-
teins that are currently available to study neural
circuits, see Yizhar et al. (2011a). The most com-
monly used opsin to activate neural circuits is
channelrhodopsin-2 (ChR2). ChR2 is a light-
gated cation channel that was originally isolated
from blue-green algae (Nagel et al. 2003). ChR2
is maximally activated by blue, 450–490 nm
light. When activated, absorbed photons cause
a light-induced isomerization of the all-trans
retinal protein, which leads to the opening of
the channel allowing sodium and other cations
to flow through the cell. When expressed in a
neuron, this influx of cations causes depolariza-
tion of the cell membrane at resting membrane
potentials, which will lead to the opening of
endogenously expressed voltage-gated sodium
channels to initiate an action potential. More
recently, red-shifted channelrhodopsin proteins
have been developed, which allow for the possi-
bility of exciting two genetically distinct popula-
tions of neurons within the same brain site. Vol-
vox channelrhodopsin (VChR1), the first red-
shifted channelrhodopsin charactized (Zhang
et al. 2008), has several limitations such as low
photocurrents and poor membrane trafficking.
However, C1V1, a ChR2-VChR1 hybrid, has
been engineered to increase membrane expres-
sion and has stronger photocurrents, making it
more suitable for excitation of neural circuits
(Hegemann and Moglich 2011; Yizhar et al.
2011b).
Optogenetic inactivation of neural circuits is
most commonly accomplished using the light-
gated chloride pump, halorhodopsin (NpHR),
which was first discovered in arachabacteria
(Matsuno-Yagi and Mukohata 1977). Introduc-
tion of wildtype NpHR into neurons demon-
strated that photoinhibition was possible, but
initially exodogenous NpHR protein was not
sufficiently expressed at neuronal membranes
for consistent results in vivo (Gradinaru et al.
2010). Further modification of NpHR with an
added endoplasmic reticulum (ER) export sig-
nal and membrane trafficking peptide sequence,
results in robust expression at neuronal mem-
branes, which facilitated its use in vivo for neu-
ronal circuit element inhibition (Gradinaru
et al. 2010). NpHR is maximally activated by a
yellow/orange, 590-nm wavelength of light,
but can respond to a broad wavelength range
from 520 to 620 nm. When activated, NpHR
pumps chloride from the extracellular space into
the cytoplasm of the cell. When expressed in a
neuron, this results in hyperpolarization of the
cell membrane, and can decrease neuronal firing
rates (Fenno et al. 2011). Optical inhibition can
also be achieved by the use of outward proton
pumps, such as Arch (Chow et al. 2010; Fenno
et al. 2011). Arch is maximally activated by a
560-nm wavelength of light, and activation of
Arch has been shown to result in robust currents
at relatively low light outputs (Chow et al. 2010).
Although proton pumps such as Arch show
robust inhibition of neuronal membranes, it
remains undetermined the deleterious effects
these proteins have in neuronal tissues and
if they show any noncell-type-specific effects
(Fenno et al. 2011).
Expressing opsin proteins under the control
of cell-type-specific promoters is one method
of targeted manipulations of genetically de-
fined neuronal subtypes. Using this technique,
optogenetic manipulation of glutamatergic ba-
solateral amygdala (BLA) neurons to the nucle-
us accumbens (NAc) have been investigated
(Stuber et al. 2011). Calcium-calmodulin-de-
pendent protein kinase IIa (CamKIIa) is pref-
erentially expressed in glutamatergic projection
neurons in the BLA (McDonald 1992). ChR2 or
NpHR3.0 was introduced into these glutamater-
gic neurons using an adeno-associated virus
(AAV) vector with the opsins under the control
of a fragment of the CamKIIa promoter. Stereo-
taxic injection of viral constructs encoding these
proteins into the BLA results in opsin positive
neurons constrained to glutamatergic projec-
tion neurons within the BLA. As discussed in
detail below, implantation of an optical fiber
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into the NAc allows for precise control over ex-
citatory BLA inputs into the NAc. Other studies
using the CamKIIa promoter have investigated
BLA efferents to other regions of interest such as
the central amygdala (Tye et al. 2011) and to
study cortical pyramidal neurons (Aravanis
et al. 2007; Sohal et al. 2009; Yizhar et al. 2011b).
A transgenic approach is also a common
method to achieve targeted manipulation of ge-
netically defined cells. There now exist a number
of transgenic mouse lines that selectively express
ChR2 or NpHR in specific subtypes of neurons
(Arenkiel et al. 2007; Zhao et al. 2011). Whereas
this method ensures that virtually all neurons of
a specific genetically defined population will ex-
press opsin proteins, it oftentimes does not pro-
vide anatomical specificity of expression to a
discrete brain region of interest. Thus, to reli-
able target neuronal populations within specific
brain nuclei, cre recombinase-inducible expres-
sion systems have been used in conjunction with
transgenic animals expressing cre in specific
population of neurons. Using this method,
cre-inducible opsins are stereotaxically injected
into transgenic rodents expressing cre recombi-
nase in genetically identified neuronal popula-
tions (Atasoy et al. 2008; Cardin et al. 2009;
Sohal et al. 2009; Tsai et al. 2009; Witten et al.
2011). Cre-inducible AAV vectors contain DNA
cassettes with two pairs of incompatible lox sites
(LoxP and lox2722), with an opsin inserted be-
tween the two lox sites in the reverse orienta-
tion. Cre recombinase catalyzes recombination
between the two lox sites, resulting in the opsin
reversing its orientation, allowing mRNA of the
opsin to be transcribed. Thus, delivery of these
cre-inducible opsins into a specific brain region
results in opsin expression in only the geneti-
cally identified cell type in the brain region of
interest. Cholinergic interneurons in the NAc
have been targeted using this method (Witten
et al. 2010). Here, BAC transgenic choline ace-
tyltransferase (ChAT)::Cre mice were injected
with a cre-inducible double-floxed recombi-
nant AAV vector coding for ChR2 or NpHR3.0
into the NAc. Dopaminergic (DAergic) neurons
in the ventral tegmental area (VTA) have also
been targeted using a transgenic approach in
which tyrosine hydroxylase (TH)-Cre (Tsai
et al. 2009) in mice or rats (Witten et al. 2011)
or dopamine transporter (DAT)-cre mice
(Stuber et al. 2010; Cohen et al. 2012) are in-
jected with a double-floxed cre-inducible opsin
vector. The use of cre-mice paired with double-
floxed opsins, or the use of cell-type promoters,
allows for precise control over genetically de-
fined populations of neurons.
Different hardware setups have been used to
deliver light in vitro and in vivo. The most com-
mon in vitro light delivery systems include fil-
tered light from mercury arc lamps (Boyden
et al. 2005; Gunaydin et al. 2010), lasers (Stuber
et al. 2010), and LEDs (Wang et al. 2009; Ades-
nik and Scanziani 2010). In vivo, lasers coupled
to optical fibers are most commonly used to
deliver light into the brain (Cardin et al. 2010;
Stuber et al. 2011; Tye et al. 2011). For a more in-
depth description of in vivo light delivery to the
brain, see the section entitled In Vivo Optoge-
netic Strategies.
Finally, interfacing lasers with behavioral
equipment allows for optogenetics to be em-
ployed in a wide range of reward-related behav-
ioral paradigms including conditioned place
preference (Tsai et al. 2009; Lobo et al. 2010),
operant conditioning (Adamantidis et al. 2011;
Stuber et al. 2011), and Pavlovian conditioning
(Stuber et al. 2011). Combining these para-
digms with optogenetics allows for subsecond
precision control of neural circuitry time locked
to discrete behavioral events. Behavioral para-
digms associated with other neuropsychiatric
diseases, such as open field test and elevated
plus maze, have also been interfaced with in
vivo optogenetics (Tye et al. 2011). This can be
achieved using real-time video tracking hard-
ware and software to restrict optical stimulation
when the animal enters a specific area of a be-
havioral arena.
SLICE ELECTROPHYSIOLOGY PAIRED
WITH OPTOGENETICS TO PARCEL
OUT LOCAL CIRCUITS
Anatomical tracing studies and electrophys-
iological techniques using electrical stimula-
tion are often used to study the synaptic con-
nectivity within neural circuits. However, there
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are significant limitations associated with both
of these techniques. Anatomical tracing studies
often fail to address the strength and function-
ality of the synaptic connections. Electrophysi-
ological studies using electrical stimulation can
address functionality, but they often fail to de-
termine cell-type-specific projections because
most neural tissues are hetereogeneous. For ex-
ample, electrical stimulation of neurons in the
VTA will nonspecifically activate both DA and
GABA neurons, in addition to any afferents or
fibers of passage through the area. Patch clamp
electrophysiology paired with optogenetics cir-
cumvents the limitations associated with both
of these methods because it allows for cell-
type-specific activation and assessment of the
strength and functionality of these connec-
tions. Using this method, it is possible to record
from cell-type indentified postsynaptic neurons
(using mice expressing fluorescent proteins in
specific neurons or by post hoc immunohisto-
chemistry), while optically stimulating site-spe-
cific or genetically defined afferents that are
expressing ChR2. These techniques have been
successful in parsing out neural circuits involved
in addiction. In one example of this application,
Chuhma et al. (2011) used optogenetics in NAc
brain slices to define the functional connectivi-
ty of medium spiny neurons. By conditionally
expressing ChR2 in medium spiny neurons,
these authors were able to investigate connec-
tions within the striatum and projections to the
globus pallidus and substantia nigra (Chuhma
et al. 2011), as well as examine how striatal cho-
linergic interneurons can regulate function of
other populations of striatal neurons (English
et al. 2012).
Optogenetics paired with slice electrophys-
iology has also been used to examine the possi-
bility of neurotransmitter co-release. DA and
glutamate coincident signaling is crucial for a
variety of motivated behaviors including re-
sponding to motivationally significant stimuli.
A subset of tyrosine hydroxylase positive DA
neurons in the VTA also express vesicular glu-
tamate transporter-2 (VGluT2), indicating that
these DA neurons are capable of packaging
glutamate into synaptic vesicles (Hnasko et al.
2010). Furthermore, pharmacological and elec-
trophysiological studies have suggested that DA
neurons co-release glutamate (Sulzer et al. 1998;
Bourque and Trudeau 2000; Chuhma et al.
2009); however, these studies only provided in-
direct evidence as a result of the technical lim-
itations. Selective optogenetic stimulation of
ChR2-positive DAergic terminals in the NAc
shell results in excitatory postsynaptic currents
(Stuber et al. 2010; Tecuapetla et al. 2010), con-
firming that midbrain DA neurons are capable
of coreleasing glutamate in the NAc. Similar
studies have now confirmed that other neurons
that release neuromodulators, such as acetyl-
choline, are also capable of glutamate co-re-
lease, such as projection neurons in the medial
habenula (Ren et al. 2011). Utilizing optoge-
netic approaches to study neurotransmitter
release will likely yield a plethora of novel infor-
mation on the intraneuronal signaling dynam-
ics of defined neural circuits.
IN VIVO OPTOGENETIC STRATEGIES
In vivo optogenetic approaches can be used for
a variety of different experiments, from targeted
manipulations of genetically defined cells to ma-
nipulation of specific neural pathways on a phys-
iologically relevant timescale. Furthermore, uti-
lizing these in vivo optogenetic approaches in
awake and behaving animals allows for precise
control over neural circuitry time locked to dis-
crete events, necessary for determining a causal
relationship between neural function and re-
ward-related behaviors.
Delivering light into the brain is most often
accomplished by implanting an acute or chronic
optical fiber into the region of interest (Zhang
et al. 2010; Sparta et al. 2012). Using the acute
optical fiber method, a guide cannula is chron-
ically implanted in either the virus-targeted re-
gion or the projection region of interest. Then,
the optical fiber is acutely implanted immedi-
ately prior to the experiment. One benefit of
employing an acute fiber is the ability to com-
bine local pharmacology through the cannula
before implantation of the fiber. However, a ma-
jor caveat to this method is the risk of tissue
damage and fiber breakage as a result of repeat-
ed insertion and removal of the fiber. This is
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especially of concern when working with behav-
ioral paradigms that involve weeks of training
and testing. Chronic fibers, on the other hand,
are cemented into the skull during stereotaxic
surgery and allow for multiple testing sessions
over an extended time period with minimal
light loss (Sparta et al. 2012).
Chronic or acute optical fibers can be placed
in the same brain area as the virus injection to
examine the effects of optical stimulation or in-
hibition on genetically targeted cell bodies of
interest. For example, optical activation of D2
positive neurons in the NAc expressing ChR2
suppresses cocaine reward, whereas activation
of D1 positive neurons increases cocaine reward
(Lobo et al. 2010). Optical fibers can also be
placed in projection targets to investigate the
effects of altering pathway-specific circuits on
behavior. Opsins are trafficked across neuronal
membranes and can be visualized in axons and
terminals (Yizhar et al. 2011a). This technique
has been employed to look at BLA efferents to
different brain regions (see below) (Stuber et al.
2011; Tye et al. 2011), but can be used to look at
other neural circuits important in addiction
such as DAergic afferents in the NAc and pre-
frontal cortex (PFC). In addiction, this strategy
can identify neural circuit elements or genetical-
ly defined populations of neurons that are nec-
essary or sufficient for a discrete behavior such
as conditioned approach behavior to a reward-
predictive cue. For example, BLA glutamatergic
afferents to the NAc have been hypothesized
to be important in cue-triggered motivated be-
havior, but because of the inability to specifically
modulate this pathway during time-locked cues,
the causal functional role of this pathway in
cue-reward behavior was previously not well de-
fined. Using optogenetics, activation and inac-
tivation of BLA terminals in the NAc demon-
strated that this circuitry is both necessary and
sufficient for cue-driven motivated behavior
(Stuber et al. 2011).
One caveat to the optogenetic projection
targeting technique is that oftentimes afferent
fibers are bundled together, and stimulating ter-
minals in one region may also stimulate fibers of
passage that are en route to a more distal target
region. For example, DA afferents from the VTA
projecting to the PFC pass through the NAc
(Beckstead et al. 1979; Herbert et al. 1997),
and stimulation of DA terminals in the NAc
will likely also stimulate PFC-projecting fibers.
Another limitation to this method is the pos-
sibility of back-propagating action potentials.
Optical stimulation of terminals in one region
may lead to back-propagating action potentials
that activate the cell bodies, and can then acti-
vate afferents projecting to other regions. How-
ever, this limitation can be dealt with by inject-
ing lidocaine to prevent back propagating action
potentials at the level of the cell bodies of the
population of neurons that was transduced
(Stuber et al. 2011). In addition, future tech-
niques that allow for retrograde delivery of vi-
ruses encoding opsins to specific presynaptic in-
puts may circumvent some of these limitations.
CONCLUSIONS AND FUTURE DIRECTIONS
Optogenetic manipulations of the neural cir-
cuitry involved in reward and addiction have
aided in supporting and refuting many hypoth-
eses that were previously untestable as a result of
technical limitations associated with traditional
techniques. Many of the optogenetic studies to
date investigating these circuits have used opto-
genetic stimulation of neurons, but optogenetic
inhibition is likely to prove to be an even more
powerful tool to determine both necessity and
sufficiency of neural circuits for mediating re-
ward-related behaviors. In addition, combin-
ing optogenetics with in vivo monitoring tech-
niques such as in vivo electrophysiology, and
neurochemical techniques such as microdialysis
and voltammetry, allows for actuation of neural
circuits, while simultaneously measuring the
neurophysiological output. The ever-increasing
methods for targeted genetic manipulations of
neurons as well as the continued development
and refinement of optogenetic methods are un-
precedented.
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